Shah I, Madgum N

Language: English
References: 22
Page: 592-595
PDF size: 135.72 Kb.

ABSTRACT

Introduction and aim. Neonatal cholestasis constitutes for 19 to 33% of all chronic liver disease in India. Cholestasis leads to fibrosis of liver and ultimately cirrhosis. There are various methods of diagnosis of fibrosis of liver like fibroscan, aspartate transaminase to platelet ratio index (APRI) index, FIB-4, fibro index, forns index, heap score, magnetic elastography. Here we are comparing APRI index with METAVIR index in patients with neonatal cholestasis without biliary atresia and determining whether APRI index can be used as a tool to determine fibrosis in these patients. Material and methods. Patients with neonatal cholestasis without biliary atresia were included in the study. This retrospective analysis was done between 2009 and 2015. All patients underwent a liver biopsy and METAVIR index was calculated. APRI at the time of liver biopsy was determined. Results. Forty-eight patients were included in this study with mean age of 3.5 ± 2.8 months with a male: female ratio of 35:13. Metavir Index F0 was seen in was 32 (66.67%) patients, F1 in 6(12.5%), F2 in 4(8.33%), F3 in 0 and F4 in 6(12.5%) patients respectively. Mean APRI for F0-F3 was 1.38 and for F4 was 3.74 respectively. With an APRI of 1.38, the sensitivity and specificity to detect fibrosis/cirrhosis was 100% and 21.43% respectively. Conclusion. APRI is not an effective tool to measure fibrosis or cirrhosis in patients with non-BA neonatal cholestasis in Indian children.

REFERENCES

1. Yachha SK, Khanduri A, Kumar M, Sikora SS, Saxena R, Gupta RK, Kishore J. Neonatal cholestasis syndrome: an appraisal at a tertiary center. Indian Pediatr 1996; 33: 729-34.

2. Omer M, Khattak TA, Hamid Ali Shah S, Manzoor K. Etiological spectrum of persistent neonatal jaundice. J Rawalpindi Med Coll 2010; 14: 87-9.

3. Bazlul Karim AS, Kamal M. Cholestatic jaundice during infancy: Experience at a tertiary care center in Bangladesh. Indian J Gastroenterol 2005; 24: 52-4.

4. Yachha SK. Recommendations- Consensus report on Neonatal Cholestasis Syndrome. Indian Pediatr 2000; 37: 845-52.

5. Scheuer PJ, Davies SE, Dhillon AP. Histopathological aspects of viral hepatitis. J Viral Hepat 1996: 3; 277-83.

6. Schreiber RA, Barker CC, Roberts EA, Martin SR, Alvarez F, Smith L, Butzner JD, et al. Biliary atresia: the Canadian experience. J Pediatr 2007; 151: 659-65, 665.e1. Epub 2007 Oct 22.

7. Pizani M, Rombouts K. Liver fibrosis: From the bench to clinical targets. Dig Liver Dis 2004; 36: 231-42.

8. Scheuer PJ, Davies SE, Dhillon AP. Histopathological aspects of viral hepatitis. J Viral Hepat 1996: 3; 277-83.

9. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343-50.

10. Kim SY, Seok JY, Han SJ, Koh H. Assessment of liver fibrosis and cirrhosis by aspartate aminotransferase-to-platelet ratio index in children with biliary atresia. J Pediatr Gastroenterol Nutr 2010; 51: 198-202.

11. Wai CT, Greenson, JL, Fontana RJ, Kalbfleich JD, Marrero JA, Conjeevaram HS, Lok AS. A simple non-invasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-26.

12. Dickson ER, Murtaugh PA, Wiesner RH, Grambsch PM, Fleming TR, Ludwig J, LaRusso NF, et al. Primary sclerosing cholangitis: refinement and validation of survival models. Gastroenterology 1992; 103: 1893-901.

13. Roll J, Boyer JL, Barry D, Klatskin G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N Engl J Med 1983; 308: 1-7.

14. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-81.

15. Castera L, Negre I, Samii K, Buffet. Pain experienced during percutaneous liver biopsy. Hepatology 1999; 30: 1529-30.

16. Dienstag JL. The role of liver biopsy in chronic hepatitis C. Hepatology 2002; 36: 152-60.

17. Bedossa P, Darge’re D, Paradis V. Sampling variability of liver biopsy in chronic hepatitis C. Hepatology 2003; 38: 1449- 57.

18. Batts KP, Ludwig J. Chronic hepatitis an update on terminology and reporting. Am J Surg Pathol 1995; 19: 1409-17.

19. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, Feng ZZ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.

20. Siddique I, El-Naga HA, Madda JP, Memon A, Hasan F. Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol 2003; 38: 427-32.

21. de Lédinghen V, Le Bail B, Rebouissoux L, Fournier C, Foucher J, Miette V, Castéra L, et al. Liver stiffness measurement in children using FibroScan: Feasibility study and comparison with Fibrotest, aspartate transaminase to platelets ratio index, and liver biopsy. J Pediatr Gastroenterolol Nutr 2007; 45: 443-50.

22. Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase- to-platelet ratio index for the prediction of hepatitis C-related fibrosis: systemic review. Hepatology 2007; 46: 912-21.